GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocartis Group NV (CHIX:BCARTb) » Definitions » Short Interest

Biocartis Group NV (CHIX:BCARTB) Short Interest


View and export this data going back to 2016. Start your Free Trial

What is Biocartis Group NV Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Biocartis Group NV's Short Interest

For the Diagnostics & Research subindustry, Biocartis Group NV's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocartis Group NV's Short Interest Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocartis Group NV's Short Interest distribution charts can be found below:

* The bar in red indicates where Biocartis Group NV's Short Interest falls into.


;
;

Biocartis Group NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocartis Group NV (CHIX:BCARTb) » Definitions » Short Interest
Comparable Companies
XBRU:MDXH TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN LH DGX WAT XPAR:BIM EXAS RVTY XPAR:ERF ASX:SHL CRL
Traded in Other Exchanges
N/A
Address
Generaal de Wittelaan 11 B, Mechelen, BEL, 2800
Website
https://www.biocartis.com
Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an MDx Idylla molecular diagnostic system for oncology and infectious disease segments. Its products include EGFR mutation assay, BRAF mutation test, NRAS mutation test, respiratory panel, etc. The firm derives the majority of its revenues from product sales.

Biocartis Group NV Headlines

No Headlines